GRANGE DAVID L 4

What Happened

• David L. Grange, a director of Tonix Pharmaceuticals (TNXP), received a derivative award on 2026-05-12 covering 22,700 shares. The Form 4 reports the acquisition price as $0.00 (this filing reflects an option/award grant, not a cash purchase or sale).

Key Details

• Transaction date: 2026-05-12; filing date (accession): 2026-05-14 (filed two days after the transaction).
• Reported price: $0.00 (derivative award).
• Shares owned after transaction: not specified in the provided data.
• Footnote: The option was granted under the Issuer’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the grant date or the Issuer’s 2027 Annual Meeting of Stockholders.
• Filing timeliness: No late filing flag provided; the Form 4 was filed within the typical two-business-day window.

Context

• This was a grant of a derivative award (option-like award) rather than an open-market buy or sale. The award vests over time/trigger (earlier of one year or 2027 annual meeting), so Grange does not obtain vested shares immediately. Such equity grants are common as director compensation and should not be interpreted alone as a market sentiment signal.